What does this research mean for the field?

Menopausal hormone therapy (MHT) may decrease the risk of hepatocellular carcinoma, but does not affect the risk of intrahepatic cholangiocarcinoma in women. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the effects of menopausal hormone therapy on the risk of liver cancer in women, focusing on specific types.

March 25, 2026Open Access

Menopausal hormone therapy and risk of liver cancer in a swedish population-based cohort study

Key Points

To investigate the effects of menopausal hormone therapy on the risk of liver cancer in women, focusing on specific types.
Analyzed a Swedish population-based cohort
Evaluated the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Compared liver cancer rates between hormone therapy users and non-users
Menopausal hormone therapy is associated with a decreased risk of hepatocellular carcinoma
No significant impact of hormone therapy on the risk of intrahepatic cholangiocarcinoma

Abstract

MHT in women may decrease the risk of hepatocellular carcinoma, but not intrahepatic cholangiocarcinoma.

Menopausal hormone therapy and risk of liver cancer in a swedish population-based cohort study

Key Points

Abstract

Cite This Study